Gastrointestinal Cancer | Specialty

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Questions Remain in Localized Pancreatic Cancer as More Treatment Modalities Emerge

January 10th 2020

Pablo Ferraro, MD, discusses some of the latest developments in pancreatic cancer treatment and the potential role of emerging modalities under exploration.

Oncologists Outline Ongoing Research Efforts Across GI Cancers, GBM

January 10th 2020

Faculty from a 2019 OncLive® State of the Science Summit™ on Gastrointestinal Malignancies highlight the exciting research being conducted at their respective institutions.

Expert Highlights Immunotherapy Combo Strategies in Relapsed/Refractory CRC

January 10th 2020

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

FDA Approves Avapritinib for PDGFRA Exon 18+ GIST

January 10th 2020

The FDA has approved avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Dr. He on Future Treatment for Patients With Hepatocellular Carcinoma

January 10th 2020

Aiwu Ruth He, MD, discusses the combination regimen of bevacizumab and atezolizumab in patients with advanced-stage hepatocellular carcinoma.

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

January 9th 2020

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Olaparib Expands Options in Metastatic Pancreatic Cancer

January 7th 2020

A. Craig Lockhart, MD, MHS, discusses the current treatment landscape of pancreatic cancer and how the introduction of olaparib in the frontline maintenance setting may benefit patients.

Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer

January 7th 2020

Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

January 7th 2020

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Challenges Remain With Pancreatic Cancer Staging

January 6th 2020

Afonso Ribeiro, MD, discusses imaging modalities as well as challenges and future goals for the pancreatic cancer paradigm.

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

January 4th 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Novel Agents and Strategies Propelling Progress in Gastric Cancer

January 3rd 2020

Mike Cusnir, MD, discusses the evolving gastric cancer paradigm.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

FDA Approves Olaparib for Frontline Maintenance in Pancreatic Cancer

December 30th 2019

The FDA has approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

Dr. Vulfovich on Broad Molecular Profiling in mCRC

December 20th 2019

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).